In the August 2017 edition of the European Journal of Surgical Oncology (EJSO) we found this article, “Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent”.
From the Abstract for this August 2017 EJSO article we get this new information about the breast implants associated lymphoma and blood cancer situation as it has developed in the United Kingdom (UK):
Methods: Between 2012 and 2016, 23 cases of BIA-ALCL were diagnosed in 15 regional centres throughout the UK. Data on breast implant surgeries, clinical features, treatment and follow-up were available for 18 patients….
Discussion: BIA-ALCL is a rare neoplasm with a good prognosis. Our data support the recommendation that stage I disease be managed with surgery alone. Adjuvant chemotherapy may be required for more invasive disease and our experience has shown the efficacy of Brentuximab as a second line treatment.
For a different perspective on this medical issue, you can take a look at this article, “What’s Your Micromort? A Patient-Oriented Analysis of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)”, which was published in the September 2017 edition of the Aesthetic Surgery Journal (ASJ).
From an August 23, 2017 press release from the ASJ, which is the official publication of the American Society for Aesthetic Plastic Surgery, we take this snippet:
William P. Adams, Jr. MD, one of the study’s authors explains, “Unfortunately, patients are getting the wrong information, and this study is critical to correcting that….”
For what is worth, here is that press release: “ASJ Study Puts The Risk Of Death From Breast Implant-Associated Anaplastic Large Cell Lymphoma Into Plain Perspective for Patients”.
Our law firm is investigating breast implants associated lymphoma and blood cancer cases.[Read this article in full at original source]
Strictly Confidential, No Obligation.